Advertisement

Topics

Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review

14:11 EDT 9 Aug 2017 | SCRIP

Company says that while FDA has focused on expediting approval of third and fourth generics, it has not done so...

      

Related Stories

 

Original Article: Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review

NEXT ARTICLE

More From BioPortfolio on "Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review"

Quick Search
Advertisement